MLYS:NSD-Mineralys Therapeutics, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 16.18

Change

+0.48 (+3.06)%

Market Cap

N/A

Volume

0.70M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.03 (-0.46%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.86 (-0.38%)

USD 65.38B
ARGX argenx NV ADR

+7.09 (+1.24%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+0.88%)

USD 32.75B
ONC BeiGene, Ltd.

-1.27 (-0.49%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.31 (+0.93%)

USD 18.35B
SMMT Summit Therapeutics PLC

+0.17 (+0.87%)

USD 13.53B
INSM Insmed Inc

-0.95 (-1.29%)

USD 11.84B
INCY Incyte Corporation

-0.18 (-0.27%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.84 (-1.50%)

USD 11.29B

ETFs Containing MLYS

BBC Virtus LifeSci Biotech Cl.. 1.50 % 0.79 %

+0.18 (+0.91%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.44% 85% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.44% 85% B 89% A-
Trailing 12 Months  
Capital Gain 24.46% 80% B- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.46% 80% B- 77% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.77% 58% F 57% F
Dividend Return 4.77% 58% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.83% 90% A- 65% D
Risk Adjusted Return 17.79% 78% C+ 55% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector